Advanced and recurrent endometrial cancer: State of the art and future perspectives

Francesca Tronconi, Camilla Nero, Elena Giudice, Vanda Salutari, Lucia Musacchio, Caterina Ricci, Maria Vittoria Carbone, Viola Ghizzoni, Maria Teresa Perri, Floriana Camarda, Marica Gentile, Rossana Berardi, Giovanni Scambia, Domenica Lorusso

Risultato della ricerca: Contributo in rivistaArticolo in rivista


Patients with primary metastatic/recurrent endometrial cancer have poor prognosis and available therapeutic options are limited. Current treatment is mainly based on platinum-based chemotherapy. Recently, the Food and Drug Administration (FDA) granted approval for the combination of pembrolizumab and lenvatinib for endo-metrial cancer patients without microsatellite instability (MSS) progressing on a previous line of therapy while European Medicines Agency (EMA) approved the combination for all comers patients failing previous platinum treatment. Anti programmed cell death protein-1 (PD-1) dostarlimab (TSR-042) was approved as monotherapy in patients with advanced, microsatellite instable (MSI) endometrial cancer progressing to platinum treatment. Phase II-III clinical trials in metastatic endometrial cancer are mainly focused on target therapies and immu-notherapy as single agents or in combination. Unfortunately, most of these trials are lacking of predictive bio-markers of response to select patients most or at least likely to benefit from those treatments.
Lingua originaleEnglish
pagine (da-a)1-13
Numero di pagine13
Stato di pubblicazionePubblicato - 2022


  • Chemotherapy
  • Hormonal therapy
  • Target therapy
  • Metastatic endometrial cancer
  • Radiation treatment
  • Immunotherapy


Entra nei temi di ricerca di 'Advanced and recurrent endometrial cancer: State of the art and future perspectives'. Insieme formano una fingerprint unica.

Cita questo